Shire plc: CHMP Recommends EU Marketing Authorisation of lanadelumab for the Prevention of HAE Attacks CHMP Recommends EU Marketing Authorisation of lanadelumab for the Prevention of HAE Attacks -       If approved, lanadelumab would be the first monoclonal antibody for the preventive treatment of...